You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company plans to add 150 to 200 new employees and is quadrupling its space in Pleasanton, California, including a manufacturing site for its microfluidic chips.
The collaboration will use 1CellBio's InDrop system to examine inflammatory and immunological conditions in patients and develop disease profiles.
The automated, whole-genome directional genomic hybridization system can measure de novo random, low-frequency, and complex structural variations.
In PNAS this week: computational approach to bring together single-cell data, systems genetic analysis of Anopheles gambiae polymorphism, and more.
Multi-Omics Factor Analysis looks for underlying causes of tumor variations by parsing and weighting genomic, epigenomic, transcriptomic, proteomic, and metabolomic data.
The BigSCale tool incorporates a numerical model that integrates data processing, clustering, convoluting, and differential expression analysis.
The startup plans to harness single-cell genomics and computational analysis to discover therapies for autoimmune disease and cancer.
A 30 percent decrease in instrument revenue was tempered by a 23 percent uptick in consumables revenue.
At the Association of Biomolecular Research Facilities annual meeting this week, the ABRF Genomics Research Group presented results from its comparison of single-cell RNA sequencing platforms.
The two studies used Drop-seq RNA profiling to discover essentially all cell types and establish cell lineages in a model organism flatworm.
A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.
According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.
In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.